Rezultati pretraživanja
  1. prije 13 sati

    A positive development on the front. We need to do more to support a competitive biological marketplace that will help lower costs. FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake via

  2. prije 16 sati

    Our latest STAT Report dives into the regulatory and manufacturing challenges face — and possible solutions to bring them more success. Learn more here:

  3. 4. velj

    FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake..

  4. 3. velj

    What will it take to deliver on the promise of in the U.S.? A new special report by answers this questions and takes a deep dive look into these life-saving therapies. Read the report now:

  5. The issue is not , it's the forced switching of pts well managed on a . Decision was rushed and uninformed. Consequently, Albertans have many questions, are rightly upset and deserve so much more

  6. 7. sij
  7. Prikaži ovu nit
  8. 12. pro 2019.

    is advancing the initiative, which will finally result in provincial insurance plan shifting patients to lower-cost and equally effective biosimilars. This is an important advance for patients, since savings can be deployed 1/2

    Prikaži ovu nit
  9. : "The major policy change in favour of the less-expensive versions, called biosimilars, will take effect by next summer and is expected to save $227-million to $380-million over the next four years."

  10. 7. pro 2019.
  11. 22. stu 2019.

    As of 2018, accounted for 98% of the infliximab used in Norway, 92% in Britain, 78% in Sweden & 60% in France, according to ⁦⁩. In Canada, that figure was 8%. Others argue a lack of to make a switch.

  12. can offer patients more affordable and accessible options for biological therapies. But do we fully understand how they are manufactured, approved and regulated? Here's a comprehensive recap:

  13. 22. kol 2019.

    Notable op-ed from in : Time to Throw In the Towel on . My $0.02: Too soon. Fix (prices not in ) and change incentives to jump start biosim market. OW, non-market interventions will get traction.

  14. 5. kol 2019.

    The great war..An exclusive club for a breast cancer blockbuster in the US is turning into a crowded chamber. Roche's old horse is set to see newborns Amgen/Allergan, Biocon/Mylan, Celltrion/Teva, Samsung/Biogen & Pfizer...Read more

  15. B.C. Health Minister pleased that Health Canada taking 'corrective measures' with pharmaceutical company over pharma ads criticizing policy, by via

  16. As an insurer with experience, Green Shield Canada knows: “ are a prime example of that smart decision making that will ultimately protect the existence and viability of the Canadian health-care system.”

  17. Private insurer Green Shield Canada applauds B.C.’s switching intitiative. “The decision to embrace is not a difficult one – it’s just logical.”

  18. 1. svi 2019.

    There are that have failed to launch due to patent litigation and patent related issues. New legislation by and could help remedy this issue:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.